HCPLive Five - Dermatology Updates at DERM 2025 NP/PA Conference

Many clinicians, including dermatologists, physician associates (PAs), and nurse practitioners (NPs), attended the 2025 Dermatology Education Foundation DERM NP/PA CME Conference in Las Vegas, an event designed to bring together those working in the field of dermatology for networking, informative sessions, and presentations of recent data.

The annual conference featured a variety of recent data that spanned across a wide range of dermatologic disease states, including alopecia areata, psoriasis, hidradenitis suppurativa (HS), atopic dermatitis, and more. Unique insights were provided by session presenters regarding disease management, disease pathophysiology, and therapeutic options for patients.

As part of the HCPLive editorial team’s on-site coverage of the DERM 2025 meeting, the team reported directly from the floor of the meeting, conducting exclusive interviews with different experts in the field of dermatology and spotlighting their sessions or recent trial data. This edition of the 'HCPLive Five’ includes a set of 5 standout interviews:

Highlighting Recent Topical Options for Psoriasis, with Linda Stein Gold, MD

While there has been a huge increase in the number of options available for treating psoriasis, including a variety of topical options, many clinicians may still resort to topical steroids over other non-steroidal alternatives. Linda Stein Gold, MD, of the Henry Ford Health System, spoke in her on-site interview at DERM 2025 about some of the best non-steroidal topical medications for patients with psoriasis, highlighting that potent topical steroids are not a long-term solution to the treatment of this inflammatory skin condition.

Discussing Risankizumab Efficacy in Genital and Scalp Psoriasis, with Eingun James Song, MD

In another interview conducted at DERM 2025, Eingun James Song, MD, highlighted his team’s 16-week findings from the phase 4 UnlIMMited study, noting the efficacy and safety of risankizumab for genital and scalp psoriasis. The director of clinical research at Frontier Dermatology in Mills Creek, Washington, spoke on some of the most notable highlights from the study’s design and about some of the biggest takeaways regarding risankizumab’s use in genital and scalp psoriasis. While Song and his team’s research is ongoing, the 16-week data demonstrated several unique findings he wished to note.

Advice on Systemic Therapy Use in Pediatric Acne, with Lisa Swanson, MD

Lisa A. Swanson, MD, spoke on-site with HCPLive about the biggest takeaways from her conference presentation ‘Systemic Therapy for the Pediatric Acne Patient.’ Swanson, who serves a a dual-board-certified dermatologist and pediatric dermatologist at Ada West Dermatology, explained several clinical pearls from her session on the use of systemic therapy for acne in young patients. Swanson noted the value of dermatologists being well-prepared to treat acne, which she added can consume a significant portion of a clinician’s time.

Discussing Strategies to Manage Chronic Itch Among Patients, with Adam Friedman, MD

Chronic pruritus, also known as itch, was highlighted in an interview at DERM 2025 with Adam Friedman, MD, a Professor, Chair of Dermatology, Residency Program Director, Director of Translational Research, and Director of the Supportive Oncodermatology Program in the George Washington University School of Medicine & Health’s Department of Dermatology. Friedman touched on some of the issues with the liver, kidneys, and thyroid that clinicians should consider, later noting that pruritus is a potential presenting sign of different forms of malignancy.

Safety of Roflumilast Cream 0.05% in Infants and Toddlers with Atopic Dermatitis, with Adelaide Hebert, MD

In another interview at the conference, Adelaide Hebert, MD, spoke about roflumilast cream 0.05% (Zoryve) and her team’s recent conclusion that the drug may be considered safe as a treatment for those aged 2 - 5 years with atopic dermatitis. These new phase 2 findings were drawn from the INTEGUMENT-INFANT trial and presented in a poster session. Hebert, a professor and director of pediatric dermatology with McGovern Medical School at UTHealth Houston, spoke in her discussion about the trial as well as a new study for patients in this age cohort with atopic dermatitis.